Hypoaldosteronism natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 26: Line 26:


===Prognosis===
===Prognosis===
*Depending on the extent of the [[hyperkalemia]] and underlying [[renal]] or [[adrenal]] condition at the time of [[diagnosis]], the [[prognosis]] of hypoaldosteronism may vary.
*Depending on the extent of the [[hyperkalemia]] and underlying [[renal]] or [[adrenal]] condition at the time of [[diagnosis]], the [[prognosis]] of hypoaldosteronism may vary.<ref name="SousaCabral2016">{{cite journal|last1=Sousa|first1=André Gustavo P|last2=Cabral|first2=João Victor de Sousa|last3=El-Feghaly|first3=William Batah|last4=Sousa|first4=Luísa Silva de|last5=Nunes|first5=Adriana Bezerra|title=Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management|journal=World Journal of Diabetes|volume=7|issue=5|year=2016|pages=101|issn=1948-9358|doi=10.4239/wjd.v7.i5.101}}</ref><ref name="pmid12133029">{{cite journal |vauthors=Ahmed A |title=Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? |journal=J Am Geriatr Soc |volume=50 |issue=7 |pages=1297–300 |year=2002 |pmid=12133029 |doi= |url=}}</ref><ref name="pmid15017529">{{cite journal |vauthors=Mangrum AJ, Bakris GL |title=Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues |journal=Semin. Nephrol. |volume=24 |issue=2 |pages=168–75 |year=2004 |pmid=15017529 |doi= |url=}}</ref>
 
*[[Prognosis]] is generally good for patients of hypoaldosteronism who receive treatment.
*[[Prognosis]] is generally good for patients of hypoaldosteronism who receive treatment.
*Untreated [[patients]] risk having [[hyperkalemia]] which is associated with [[cardiac arrhythmias]] that can be [[fatal]].
*Untreated [[patients]] risk having [[hyperkalemia]] which is associated with [[cardiac arrhythmias]] that can be [[fatal]].

Revision as of 14:19, 1 September 2017

Hypoaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoaldosteronism natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoaldosteronism natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoaldosteronism natural history, complications and prognosis

CDC on Hypoaldosteronism natural history, complications and prognosis

Hypoaldosteronism natural history, complications and prognosis in the news

Blogs on Hypoaldosteronism natural history, complications and prognosis

Directions to Hospitals Treating Hypoaldosteronism

Risk calculators and risk factors for Hypoaldosteronism natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

If left untreated, hypoaldosteronism leads to hyperkalemia which can alter the function of cardiac conduction pathways. Depending upon the severity of hypoaldosteronism, hyperkalemia can be a life threatening condition. When serum potassium rises above ≥ 9 mEq/L, hyperkalemia may lead to ventricular fibrillation, PEA and even cardiac arrest. Common complications of hypoaldosteronism include hyperkalemia, metabolic acidosis, hypotension, hypovolemia and hyponatremia. Depending on the extent of the hyperkalemia and underlying renal or adrenal condition at the time of diagnosis, the prognosis of hypoaldosteronism may vary. Prognosis of hypoaldosteronism is generally good for patients who receive treatment.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

References

  1. Sousa, André Gustavo P; Cabral, João Victor de Sousa; El-Feghaly, William Batah; Sousa, Luísa Silva de; Nunes, Adriana Bezerra (2016). "Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management". World Journal of Diabetes. 7 (5): 101. doi:10.4239/wjd.v7.i5.101. ISSN 1948-9358.
  2. Ahmed A (2002). "Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?". J Am Geriatr Soc. 50 (7): 1297–300. PMID 12133029.
  3. Mangrum AJ, Bakris GL (2004). "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues". Semin. Nephrol. 24 (2): 168–75. PMID 15017529.

Template:WH Template:WS